Mesothelioma is an incurable cancer of the mesothelium resulting from asbestos exposure. Many clinical trials have been found to help patients but there is still no cure. People primarily have pleural mesothelioma where the linings of the lungs have cancer, but it can also affect the lining of the abdomen[…]
Pleural Mesothelioma
Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma
Primary Outcome Measures Local tumor infiltration by cytotoxic cluster of differentiation 8 positive (CD8+) cells [ Time Frame: After cryoablation of mesothelioma up to 1 year ] Will be tested by cryoablating a small region of tumor at the time of pleural biopsy. Preponderance of T cells in ablated tumor tissue in comparison to[…]
Keytruda is Now Approved for Mesothelioma and Other Cancers
Keytruda is now approved for certain mesothelioma patients. The immunotherapy drug has been tested for mesothelioma before, but has not been approved for the treatment of it. The approval is for adult and pediatric cancers with unresectable disease and high mutational burden that have been treated and have no other[…]
Halofuginone Could Soon be Used to Treat Mesothelioma
Mesothelioma is a devastating cancer that primarily affects the lining of the lungs and abdomen. Once exposed to asbestos, it can take years to develop and after being diagnosed, there are not many options for patients. Since there is not a cure, clinical trials can give people hope and can[…]
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours (LuPARP)
Primary Outcome Measures Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: up to 6 months after last treatment cycle ] To assess the number of participants with toxicity of 177Lu-DOTA-TATE in combination with olaparib measured by NCI Common Toxicity Criteria v 5.0 Secondary Outcome Measures TTP [ Time Frame: 3[…]
Opdivo and Yervoy Work Together to Treat Pleural Mesothelioma
Mesothelioma is an aggressive cancer with very few treatment options. Patients have a low survival rate, but there is hope with clinical trials. If a clinical trial is found to be effective, patients could live longer and could eventually be cured. Opdivo and Yervoy are two immunotherapy drugs that are[…]
DuRvalumab With Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma (DREAM3R)
Patients with malignant pleural mesothelioma (MPM) that cannot be surgically removed will receive first-line treatment with standard chemotherapy of pemetrexed and cisplatin. Two-thirds of the participants in the study will be randomly assigned to also receive a new treatment called durvalumab.
Neoadjuvant Chemotherapy Does not Improve Survivability in Pleural Mesothelioma Patients
Neoadjuvant chemotherapy is typically used to shrink tumors before surgery to make it easier to remove them. It has been thought that the combination of drugs and surgery can help patients survive longer, but a study at Duke has found that it does not increase survival in pleural mesothelioma patients.[…]
Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
The purpose of this study is to offer a novel cancer vaccine called poly-ICLC (Hiltonol®) for subjects with malignant pleural mesothelioma by directly injecting the vaccine into the tumor.
Nivolumab to Help Treat Mesothelioma
A new study found that the PD-L1 inhibitor nivolumab is effective in mesothelioma. It was tested on patients and showed that it could be a safe and effective treatment for those whose first line treatments have failed. Nivolumab is an immunotherapy drug that helps the immune system fight cancer cells.[…]
Skip to content